Another piece of Ebola virus puzzle identified

A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts. Scientists at Texas Biomedical Research Institute were part of a nationwide collaborative with scientists at Gladstone Institutes, UC San Francisco and Georgia State University for a study recently published in the journal Cell.

Scientists around the globe are trying to pinpoint potential drug targets to stop Ebola virus disease, a hemorrhagic fever that killed 382 people in the latest outbreak in the Democratic Republic of Congo in 2018. Thousands of people have died from Ebola since an outbreak erupted in West Africa four years ago.

Texas Biomed Staff Scientist Olena Shtanko, Ph.D., describes this new work as a “turning point for understanding how replication of Ebola virus is modulated.” Her role in the project was to validate and test whether the interaction between an Ebola virus protein called VP 30 and a host (human) protein called RBBP6 had involvement in the life cycle of the virus. Dr. Shtanko worked on this project while in the lab of Dr. Robert Davey, a former Texas Biomed Scientist, now at Boston University.

Earlier research by scientists in California used a protein interaction map to narrow down host and virus protein interactions and then using a yeast system and an artificial proxy virus system proved the theory of this particular protein-protein interaction. However, scientists needed to use replicating virus and human immune cells to test the clinical significance of the finding.

“The interaction is important if you can show functional significance of what it does to the virus in cells that have clinical relevance,” Shtanko stressed. “If you can figure out the mechanism within these cells, then you can potentially manipulate it and stop the disease progression.”

Texas Biomed Staff Scientist Eusondia Arnett, Ph.D., and Texas Biomed President and CEO Dr. Larry Schlesinger – both tuberculosis researchers – have expertise in working with human macrophage (immune) cells drawn from donated blood samples. “We were able to capitalize on our experience with macrophages to over- and under-express the RBBP6 (host) protein to create an effective model for this important Ebola virus research,” Arnett said.

By over- and under-expressing the RBBP6, Shtanko was able to test what impact the protein had on the growth of Ebola virus in the macrophages. Shtanko said the results were striking. When the host protein was under-expressed, the viral replication went up exponentially. She found similar results when working with vascular cells, which are also key to Ebola virus replication in an infected patient.

The study was also an example of the Institute’s new team science environment; whereby, researchers capitalize not only on the resources available at Texas Biomed but the expertise of its cross-functional teams (i.e. Ebola virus and macrophage biology) to produce beneficial results.

Texas Biomed has one of only a handful of Biosafety Level 4 laboratories in the United States where scientists can safely work with deadly pathogens, such as Ebola virus, which cause diseases for which there is no cure. This allowed for the study to be completed in human cells using live virus. And, Shtanko explained, the study turnaround was very short, so having the expertise of Arnett and Schlesinger was integral in creating the human macrophage cells necessary to complete the study.

###

This work was supported by two grants from the National Institutes of Health:

P01120943, “CIS AND TRANS-ACTING FACTORS THAT MODULATE EBOLA VIRUS RNA SYNTHESIS” – Gaya Amarasinghe of Washington University was Principal Investigator along with Dr. Rob Davey.

R01AI114814, “EMERGING VIRUS-HOST CELL PROTEIN INTERACTION NETWORKS” – Douglas LaCount of Purdue University was Principal Investigator along with Dr. Rob Davey.

The work was also funded by a grant from the Texas Biomedical Forum awarded to Dr. Shtanko and Dr. Arnett in 2017 titled “Regulation of VPS34 complex in macropinocytosis.”

Texas Biomed is one of the world’s leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. The Institute is home to the Southwest National Primate Research Center (SNPRC) and provides broad services in primate research. SNPRC contributes to a national network of National Primate Research Centers (NPRCs) with specialized technologies, capabilities and primate resources, many of which are unique to the SNPRC. The Center also serves investigators around the globe with research and technical procedures for collaborative projects. For more information on Texas Biomed, go to http://www.TxBiomed.org or for more information on SNPRC, visit http://www.SNPRC.org